Interview with Dr. Bel Mekonnen, Hager Biosciences
Reaxys delivers all the required data for pharmaceutical R&D through one interface
As a developer of lead compounds, Hager Biosciences needs reliable access to accurate medicinal chemistry and synthesis data. As a start-up, they need rapid research workflows to remain competitive. Dr. Bel Mekonnen, CEO of Hager Biosciences, considers Reaxys and Reaxys Medicinal Chemistry perfect for his company's needs.
Hager Biosciences is a start-up drug discovery organization working in the pre-clinical space. The researchers seek to develop lead compounds for unmet medical needs. They need access to reliable and accurate medicinal chemistry data along with compound synthesis methodologies. Searching for such information in disparate sources and then having to normalize it would take considerable time.
Dr. Bel Mekonnen, CEO of Hager Biosciences, is really pleased with the combined Reaxys and Reaxys Medicinal Chemistry research solution. Accessing them through a single user interface is perfect for the needs of his company. His researchers can get medicinal chemistry data and compound reaction and synthesis information in one place. He believes that the data curation and normalization are excellent and that the two products are very well suited to lead identification and validation. Because they can see the methodology without having to read the primary reference, it also saves them time.
Reaxys extracts information about compound synthesis and protocols, saving us considerable time. Dr. Bel Mekonnen, CEO of Hager Biosciences
Dr. Mekonnen is certain that he and his team will continue using Reaxys for their pre-clinical drug discovery work. It gives them flexibility when planning synthesis and helps them discover new pathways. They also find Reaxys Medicinal Chemistry valuable for assessing how compounds in the same target space as theirs have fared. It is valuable information that helps them succeed.
Reaxys and Reaxys Medicinal Chemistry are perfect for our needs. Dr. Bel Mekonnen, CEO of Hager Biosciences
Download the full case study to learn more (PDF, 450kb)